The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 10, 2012, Pages 2549-2557

  Ambrose, C S ^a   Dubovsky, F ^a   Yi, T ^a   Belshe, R B ^b   Ashkenazi, S ^c,d  

^a MEDIMMUNE   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; SHORT ACTING DRUG; THEOPHYLLINE; TRIVALENT INACTIVATED INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; ASTHMA; BRONCHOSPASM; CHILD; CONTROLLED STUDY; CROUP; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; IRRITABILITY; LOWER RESPIRATORY TRACT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINORRHEA; SIDE EFFECT; SYMPTOM; UPPER RESPIRATORY TRACT; UPPER RESPIRATORY TRACT INFECTION; VIRUS CULTURE; WHEEZING;

ADOLESCENT; ASTHMA; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; FEMALE; HOSPITALIZATION; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; RESPIRATORY SOUNDS; TREATMENT OUTCOME; VACCINATION; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 84869103013     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-012-1595-9     Document Type: Article

References (16)

1. Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S; International Study of Asthma and Allergies in Childhood Phase Three Study Group (2009) Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 64(6):476-483
2. Neuzil KM, Wright PF, Mitchel EF Jr, Griffin MR (2000) The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr 137(6):856-864
3. Belshe RB, Ambrose CS, Yi T (2008) Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 26(Suppl 4):D10-D16
4. Belshe RB, Edwards KM, Vesikari T, Black SV,Walker RE, Hultquist M, Kemble G, Connor EM; CAIV-T Comparative Efficacy Study Group. (2007) Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356(7):685-696
5. European Medicines Agency (2011) Fluenz: EPAR-Product Information. Available online at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/001101/WC500103709.pdf. Accessed 8 Mar 2012
6. Health Canada (2011) FluMist Product Monograph. Available online at: http://www.astrazeneca.ca/documents/ProductPortfolio/FLUMIST-PM-en.pdf. Accessed 8 Mar 2012
7. Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B; CAIV-T Asthma Study Group (2006) Comparison of the efficacy and safety of live attenuated coldadapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 25(10):860-869
8. Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith DD, Klemola T, Biolek J,Kühr J, Bujnowski T,Desgrandchamps D, Cheng SM, Skinner J, Gruber WC, Forrest BD; CAIV-T Study Group (2006) Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 25(10):870-879
9. Redding G,Walker RE, Hessel C, Virant FS, Ayars GH, Bensch G, Cordova J, Holmes SJ, Mendelman PM (2002) Safety and tolerability of cold-Adapted influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 21(1):44-48
10. Gaglani MJ, Piedra PA, Riggs M, Herschler G, Fewlass C, Glezen WP (2008) Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J 27 (5):444-452
11. Center for Biologics Evaluation and Research (2007) Vaccines and related biological products advisory committee meeting transcript. US Food and Drug Administration, Department of Health and Human Services, Washington, DC. Available online at: http://www.fda.gov/ohrms/dockets/ac/07/transcripts/2007- 4292t1.pdf. Accessed 7 Oct 2011
12. Kotaniemi-Syrjänen A, Reijonen TM, Korhonen K, Waris M, Vainionpää R, Korppi M (2008) Wheezing due to rhinovirus infection in infancy: Bronchial hyperresponsiveness at school age. Pediatr Int 50(4):506-510
13. Guilbert TW, Singh AM, Danov Z, Evans MD, Jackson DJ, Burton R, Roberg KA, Anderson EL, Pappas TE, Gangnon R, Gern JE, Lemanske RF Jr (2011) Decreased lung function after preschool wheezing rhinovirus illnesses in children at risk to develop asthma. J Allergy Clin Immunol 128(3):532-538.e10
14. Jackson DJ, Evans MD, Gangnon RE, Tisler CJ, Pappas TE, Lee WM, Gern JE, Lemanske RF Jr (2012) Evidence for a causal relationship between allergic sensitization and rhinovirus wheezing in early life. Am J Respir Crit Care Med 185(3):281-285
15. Ambrose CS, Yi T, Falloon J (2011) An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years. Influenza Other Respi Viruses 5(6):389-397
16. Izurieta HS, Haber P, Wise RP, Iskander J, Pratt D, Mink C, Chang S, Braun MM, Ball R (2005) Adverse events reported following live, cold-Adapted, intranasal influenza vaccine. JAMA294(21):2720-2725